亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Patient Decision Aid About Conservative Kidney Management in Advanced Kidney Disease: A Randomized Pilot Trial

医学 肾脏疾病 随机对照试验 损耗 收据 医疗保健 家庭医学 内科学 物理疗法 计算机科学 经济增长 万维网 经济 牙科
作者
Susan Wong,Taryn Oestreich,David K. Prince,J. Randall Curtis
出处
期刊:American Journal of Kidney Diseases [Elsevier BV]
卷期号:82 (2): 179-188 被引量:5
标识
DOI:10.1053/j.ajkd.2022.12.007
摘要

Available decision aids for patients about treatment of advanced chronic kidney disease (CKD) often lack information on conservative kidney management (CKM). We assessed the feasibility and acceptability of a decision aid on CKM among patients with advanced CKD and their family members.Randomized pilot trial.Patients aged≥75 years with stage 4 or 5 CKD and their family members at 4 medical centers in the greater Seattle area between August 2020 and December 2021.Usual care with or without a decision aid on CKM.Acceptability was assessed by attrition rates between the initial study visit (T1) and the 3-month follow-up evaluation (T3). The primary outcome and measure of feasibility was the proportion of participants who discussed CKM with a health care provider between T1 and T3.We randomized 92 patients of whom 86 (55.8% male; age 82±6 years; 82.6% White) completed T1-42 in the usual care arm and 44 in the usual care plus decision aid arm-and 56 family members of whom 53 (18.9% male; age 71±11 years; 86.8% White) completed T1-20 in usual care arm and 33 in the usual care plus decisions aid arm. The attrition rates were 21% versus 21% (P=1.0) for patients, and 10% versus 18% (P=0.46) for family members in the usual care versus usual care plus decisions aid arms. Receipt of the decision aid significantly increased discussion of CKM with a health care provider for patients (26.4% vs 3.0%, P=0.007) and family members (26.9% vs 0, P=0.02).Possible limited generalizability because participants were a relatively homogenous group. The decision aid focuses on CKM and may be less applicable to those with limited knowledge of kidney replacement therapies.A CKM decision aid was feasible and acceptable, and increased discussion of this treatment option with health care providers. This aid may serve as a useful adjunct to the currently available educational tools on treatments for advanced CKD.Grant from a not-for-profit entity (National Palliative Care Research Center).Registered at ClinicalTrials.gov with study number NCT04919941.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
nacoo发布了新的文献求助10
8秒前
zzx完成签到,获得积分10
12秒前
14秒前
大气大侠发布了新的文献求助10
18秒前
wangfaqing942完成签到 ,获得积分10
20秒前
顾矜应助科研通管家采纳,获得10
32秒前
脑洞疼应助科研通管家采纳,获得10
32秒前
墨绾菩提应助科研通管家采纳,获得30
33秒前
土豪的摩托完成签到 ,获得积分10
45秒前
大个应助张张采纳,获得10
48秒前
KY2022完成签到,获得积分10
51秒前
iShine完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
陆康完成签到,获得积分10
1分钟前
梨花月应助陆康采纳,获得10
1分钟前
2分钟前
斯文钢笔发布了新的文献求助10
2分钟前
小李老博完成签到,获得积分10
2分钟前
上官若男应助斯文钢笔采纳,获得10
2分钟前
2分钟前
ys完成签到 ,获得积分10
2分钟前
Haibara完成签到,获得积分10
2分钟前
3分钟前
zengyuewei发布了新的文献求助10
3分钟前
3分钟前
3分钟前
不吃垃圾食品完成签到 ,获得积分10
4分钟前
慕青应助黄康采纳,获得30
4分钟前
Owen应助科研通管家采纳,获得10
4分钟前
Copyright应助科研通管家采纳,获得10
4分钟前
5分钟前
5分钟前
5分钟前
5分钟前
5分钟前
5分钟前
5分钟前
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
Electrode Potentials 550
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6967714
求助须知:如何正确求助?哪些是违规求助? 8648878
关于积分的说明 18339936
捐赠科研通 6421233
什么是DOI,文献DOI怎么找? 3088257
关于科研通互助平台的介绍 2139703
邀请新用户注册赠送积分活动 2064762